These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 32173900

  • 1. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.
    Morita A, Tani Y, Matsumoto K, Yamaguchi M, Teshima R, Ohtsuki M.
    J Dermatol; 2020 May; 47(5):452-457. PubMed ID: 32173900
    [Abstract] [Full Text] [Related]

  • 2. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
    Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD.
    J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
    Papp KA, Gooderham M, Lynde C, Brassard D, Al-Mohammedi F, Prajapati VH, Delorme I, Albrecht L, Haydey R, Alam MS, Beecker J, Siddha S, Maguin M, Farag MS, Vieira A, Rihakova L, Langley RG.
    Arch Dermatol Res; 2024 Jun 08; 316(7):362. PubMed ID: 38850346
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A.
    N Engl J Med; 2021 Jul 08; 385(2):142-152. PubMed ID: 33891380
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W.
    J Allergy Clin Immunol; 2019 Sep 08; 144(3):750-763. PubMed ID: 31129129
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
    Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, De Simone C, Dini V, Malagoli P, Peccerillo F, Potenza C, Scala E, Skroza N, Balato A.
    Am J Clin Dermatol; 2020 Jun 08; 21(3):441-447. PubMed ID: 31786732
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A review of secukinumab in psoriasis treatment.
    Berg SH, Balogh EA, Ghamrawi RI, Feldman SR.
    Immunotherapy; 2021 Feb 08; 13(3):201-216. PubMed ID: 33203276
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Secukinumab (AIN457) for the treatment of psoriasis.
    López-Ferrer A, Vilarrasa E, Puig L.
    Expert Rev Clin Immunol; 2015 Feb 08; 11(11):1177-88. PubMed ID: 26428036
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
    Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G, SUPREME Study Group.
    Br J Dermatol; 2018 Nov 08; 179(5):1072-1080. PubMed ID: 29704432
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.